Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)
A Phase I Safety, Dose Escalating Study of MultiGeneAngio in Patients With Peripheral Arterial Disease
Sponsor: MultiGene Vascular Systems Ltd.
Listed as NCT00390767, this PHASE1/PHASE2 trial focuses on Claudication and PAD and remains ongoing. Sponsored by MultiGene Vascular Systems Ltd., it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MultiGene Vascular Systems Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .